Listen: Shocking FDA rejections, a setback in longevity science, & the latest on Covid-19 immunity

https://www.statnews.com/2020/08/20/shocking-fda-rejections-a-setback-in-longevity-science-the-latest-on-covid-19-immunity/?utm_source=STAT+Newsletters&utm_campaign=0652f749cd-EMAIL_CAMPAIGN_2020_08_20_08_23&utm_medium=email&utm_term=0_8cab1d7961-0652f749cd-149692869

Is longevity research over-hyped?

What can patients who have recovered from Covid-19 teach us about vaccines for the disease? Has the FDA suddenly become more stringent about approving new drugs? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. 

First, we break down a pair of shocking FDA rejections, for therapies from Gilead Sciences and BioMarin Pharmaceutical, and what they might portend. Next, STAT’s Matthew Herper joins us to explain some disappointing results for Unity Biotechnology and the implications for longevity research.

Finally, medicinal chemist and blogger Derek Lowe calls in to discuss the latest research on coronavirus immunity and the development of vaccines for Covid-19.

Listen here.